Skip to main content

Table 3 Clinical outcomes (HbA1c, BMI, systolic blood pressure, cholesterol (total, HDL, LDL]) of the intervention and control group at 6 and 12 months

From: Effects of the Proactive interdisciplinary self-management (PRISMA) program on self-reported and clinical outcomes in type 2 diabetes: a pragmatic randomized controlled trial

  Baseline – 0 months RCT phase – 6 months Extension of the RCT phase – 12 months
Clinical
parameters
푛 (%)/mean ± SD/median (25–75 quartiles)
Intervention group (n = 95) Control group (n = 98) Intervention group (n = 95) Control group (n = 98)   Intervention group (n = 95) Control group
(n = 98)
 
  Value Missing Value Missing Value Missing Value Missing Mean difference (95% CI) Value Missing Value Missing Mean difference (95% CI)
HbA1c in mmol/mol 50.7 ± 8.5 70 (73.7) 54.7 ± 11.7 75 (76.5) 51.1 ± 11.0 71 (74.7) 58.2 ± 14.3 74 (75.5) −7.08 (− 14.49–0.33) 53.91 ± 7.72 73 (76.8) 56.2 ± 10.3 82 (83.7) − 2.28 (− 8.29–3.63)
BMI 28.5 ± 4.3 64 (67.4) 30.8 ± 5.1 66 (67.3) 28.5 ± 4.3 58 (61.1) 30.7 ± 5.3 44 (44.9) −2.17 (− 4.25– − 0.09)* 29.9 ± 4.7 48 (50.5) 31.2 ± 6.3 50 (51.0) − 1.29 (− 3.56–0.98)
Systolic blood pressure in mmHG 139.35 ± 15.0 58 (61.1) 135.59 ± 14.93 61 (62.2) 142.19 ± 17.56 59 (62.1) 139.54 ± 18.74 41 (41.8) 2.65 (− 5.09–10.39) 138.51 ± 13.35 50 (52.6) 137.94 ± 13.68 48 (49.0) 0.57 (−4.95–6.09)
Cholesterol in mmol/L 4.47 ± 1.45 78 (82.1) 4.08 ± 1.21 80 (81.6) 4.10 ± 0.97 77 (81.1) 3.92 ± 0.81 77 (78.6) 0.18 (− 0.40–0.76) 4.09 ± 0.90 80 (84.2) 4.26 ± 0.98 87 (88.8) − 0.18 (− 0.94–0.59)
HDL in mmol/L 1.25 ± 0.3 78 (82.1) 1.06 ± 0.3 80 (81.6) 1.11 ± 0.31 77 (81.1) 1.26 ± 0.30 77 (78.6) − 0.15 (− 0.34–0.05) 1.24 ± 0.39 80 (84.2) 1.10 ± 0.44 87 (88.8) 0.14 (− 0.2–0.48)
LDL in mmol/L 2.19 ± 1.7 78 (82.1) 2.27 ± 2.1 80 (81.6) 2.23 ± 0.92 77 (81.1) 2.01 ± 0.70 77 (78.6) 0.23 (− 0.31–0.77) 2.10 ± 0.56 80 (84.2) 2.17 ± 0.68 87 (88.8) − 0.07 (− 0.58–0.43)
  1. * Significant